Cargando…
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
High-dose standard-of-care chemotherapy is the only option for triple-negative breast cancer (TNBC) patients, which eventually die due to metastatic tumors. Recently, metronomic chemotherapy (mCHT) showed advantages in treating TNBCs leading us to investigate the anti-metastatic and anti-angiogenic...
Autores principales: | Scagliotti, Arianna, Capizzi, Laura, Cazzaniga, Marina Elena, Ilari, Alice, De Giorgi, Marco, Cordani, Nicoletta, Gallazzi, Matteo, Bruno, Antonino, Pelosi, Giuseppe, Albini, Adriana, Lavitrano, Marialuisa, Grassilli, Emanuela, Cerrito, Maria Grazia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749857/ https://www.ncbi.nlm.nih.gov/pubmed/36531071 http://dx.doi.org/10.3389/fonc.2022.998274 |
Ejemplares similares
-
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018) -
Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021) -
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022) -
BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022) -
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
por: Cordani, Nicoletta, et al.
Publicado: (2023)